{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:26:57Z","timestamp":1759602417594},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,12,4]],"date-time":"2008-12-04T00:00:00Z","timestamp":1228348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2008,12,4]],"date-time":"2008-12-04T00:00:00Z","timestamp":1228348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Anti-oestrogens have been the mainstay of therapy in patients with oestrogen-receptor (ER) positive breast cancer and have provided significant improvements in survival. However, their benefits are limited by tumour recurrence in a significant proportion of initially drug-responsive breast cancer patients because of acquired anti-oestrogen resistance. Relapse on such therapies clinically presents as local and\/or regional recurrences, frequently with distant metastases, and the prognosis for these patients is poor. The selective ER modulator, tamoxifen, classically exerts gene inhibitory effects during the drug-responsive phase in ER-positive breast cancer cells. Paradoxically, this drug is also able to induce the expression of genes, which in the appropriate cell context may contribute to an adverse cell phenotype. Here we have investigated the effects of tamoxifen and fulvestrant treatment on invasive signalling and compared this with the direct effects of oestrogen withdrawal to mimic the action of aromatase inhibitors.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>The effect of oestrogen and 4-hydroxy-tamoxifen on the invasive capacity of endocrine-sensitive MCF-7 cells, in the presence or absence of functional E-cadherin, was determined by Matrigel invasion assays. Studies also monitored the impact of oestrogen withdrawal or treatment with fulvestrant on cell invasion. Western blotting using phospho-specific antibodies was performed to ascertain changes in invasive signalling in response to the two anti-oestrogens versus both oestradiol treatment and withdrawal.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>To the best of our knowledge, we report for the first time that tamoxifen can promote an invasive phenotype in ER-positive breast cancer cells under conditions of poor cell-cell contact and suggest a role for Src kinase and associated pro-invasive genes in this process. Our studies revealed that although this adverse effect is also apparent for further classes of anti-oestrogens, exemplified by the steroidal agent fulvestrant, it is absent during oestrogen withdrawal.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>These data highlight a previously unreported effect of tamoxifen (and potentially further anti-oestrogens), that such agents appear able to induce breast cancer cell invasion in a specific context (absence of good cell-cell contacts), where these findings may have major clinical implications for those patients with tumours that have inherently poor intercellular adhesion. In such patients oestrogen deprivation with aromatase inhibitors may be more appropriate.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/bcr2206","type":"journal-article","created":{"date-parts":[[2008,12,4]],"date-time":"2008-12-04T19:15:54Z","timestamp":1228418154000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells"],"prefix":"10.1186","volume":"10","author":[{"given":"Annabel C","family":"Borley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Hiscox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Gee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Barrett-Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert I","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,4]]},"reference":[{"key":"2170_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jsbmb.2004.12.006","volume":"93","author":"RI Nicholson","year":"2005","unstructured":"Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D, Gee JM: Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol. 2005, 93: 257-262. 10.1016\/j.jsbmb.2004.12.006.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"2170_CR2","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1677\/erc.1.01274","volume":"13","author":"JM Gee","year":"2006","unstructured":"Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI: Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocrine-related cancer. 2006, 13 (Suppl 1): S77-88. 10.1677\/erc.1.01274.","journal-title":"Endocrine-related cancer"},{"key":"2170_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1158\/0008-5472.CAN-03-3326","volume":"64","author":"J Frasor","year":"2004","unstructured":"Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS: Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004, 64: 1522-1533. 10.1158\/0008-5472.CAN-03-3326.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"2170_CR4","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1677\/erc.1.00991","volume":"12","author":"RI Nicholson","year":"2005","unstructured":"Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM: Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer. 2005, 12 (Suppl 1): S29-36. 10.1677\/erc.1.00991.","journal-title":"Endocr Relat Cancer"},{"key":"2170_CR5","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1210\/en.2003-0705","volume":"144","author":"JM Gee","year":"2003","unstructured":"Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI: The antiepidermal growth factor receptor agent gefitinib (ZD1839\/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology. 2003, 144: 5105-5117. 10.1210\/en.2003-0705.","journal-title":"Endocrinology"},{"key":"2170_CR6","doi-asserted-by":"publisher","first-page":"7334","DOI":"10.1158\/0008-5472.CAN-05-4269","volume":"66","author":"J Frasor","year":"2006","unstructured":"Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS: Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Research. 2006, 66: 7334-7340. 10.1158\/0008-5472.CAN-05-4269.","journal-title":"Cancer Research"},{"key":"2170_CR7","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.4161\/cbt.5.12.3378","volume":"5","author":"H Visram","year":"2006","unstructured":"Visram H, Greer PA: 17beta-estradiol and tamoxifen stimulate rapid and transient ERK activationin MCF-7 cells via distinct signaling mechanisms. Cancer Biol Ther. 2006, 5: 1677-1682.","journal-title":"Cancer Biol Ther"},{"key":"2170_CR8","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.1038\/sj.onc.1209747","volume":"25","author":"LN Cowell","year":"2006","unstructured":"Cowell LN, Graham JD, Bouton AH, Clarke CL, O'Neill GM: Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas\/BCAR1, FAK and Src, via an adhesion-dependent pathway. Oncogene. 2006, 25: 7597-7607. 10.1038\/sj.onc.1209747.","journal-title":"Oncogene"},{"key":"2170_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1210\/en.2005-1293","volume":"147","author":"F Acconcia","year":"2006","unstructured":"Acconcia F, Barnes CJ, Kumar R: Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology. 2006, 147: 1203-1212. 10.1210\/en.2005-1293.","journal-title":"Endocrinology"},{"key":"2170_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-005-9120-9","volume":"97","author":"S Hiscox","year":"2006","unstructured":"Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI: Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat. 2006, 97: 263-274. 10.1007\/s10549-005-9120-9.","journal-title":"Breast Cancer Res Treat"},{"key":"2170_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10585-007-9071-0","volume":"24","author":"O Mendes","year":"2007","unstructured":"Mendes O, Kim HT, Lungu G, Stoica G: MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1\/2. Clin Exp Metastasis. 2007, 24: 341-351. 10.1007\/s10585-007-9071-0.","journal-title":"Clin Exp Metastasis"},{"key":"2170_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1210\/mend.15.1.0590","volume":"15","author":"W Feng","year":"2001","unstructured":"Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ: Potentiation of estrogen receptor activation function 1 (AF-1) by Src\/JNK through a serine 118-independent pathway. Mol Endocrinol. 2001, 15: 32-45. 10.1210\/me.15.1.32.","journal-title":"Mol Endocrinol"},{"key":"2170_CR13","first-page":"187","volume":"12","author":"M Zhong","year":"2001","unstructured":"Zhong M, Lu Z, Abbas T, Hornia A, Chatakondu K, Barile N, Kaplan P, Foster DA: Novel tumor-promoting property of tamoxifen. Cell Growth Differ. 2001, 12: 187-192.","journal-title":"Cell Growth Differ"},{"key":"2170_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ceb.2006.08.004","volume":"18","author":"RM Mege","year":"2006","unstructured":"Mege RM, Gavard J, Lambert M: Regulation of cell-cell junctions by the cytoskeleton. Curr Opin Cell Biol. 2006, 18: 541-548. 10.1016\/j.ceb.2006.08.004.","journal-title":"Curr Opin Cell Biol"},{"key":"2170_CR15","first-page":"1969","volume":"27","author":"U Jeschke","year":"2007","unstructured":"Jeschke U, Mylonas I, Kuhn C, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K, van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, Witjes JA, Schalken JA: Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence. Anticancer Res. 2007, 27: 1969-1974.","journal-title":"Anticancer Res"},{"key":"2170_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1742-4658.2006.05578.x","volume":"274","author":"S Kleiner","year":"2007","unstructured":"Kleiner S, Faisal A, Nagamine Y: Induction of uPA gene expression by the blockage of E-cadherin via Src- and Shc-dependent Erk signaling. Febs J. 2007, 274: 227-240. 10.1111\/j.1742-4658.2006.05578.x.","journal-title":"Febs J"},{"key":"2170_CR17","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-06-3021","volume":"67","author":"B Humar","year":"2007","unstructured":"Humar B, Fukuzawa R, Blair V, Dunbier A, More H, Charlton A, Yang HK, Kim WH, Reeve AE, Martin I, Guilford P: Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res. 2007, 67: 2480-2489. 10.1158\/0008-5472.CAN-06-3021.","journal-title":"Cancer Res"},{"key":"2170_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0092-8674(03)00234-4","volume":"113","author":"N Fujita","year":"2003","unstructured":"Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA: MTA3, a Mi-2\/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003, 113: 207-219. 10.1016\/S0092-8674(03)00234-4.","journal-title":"Cell"},{"key":"2170_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1023\/A:1006584624061","volume":"16","author":"AH Ree","year":"1998","unstructured":"Ree AH, Bjornland K, Brunner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O: Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis. 1998, 16: 205-215. 10.1023\/A:1006584624061.","journal-title":"Clin Exp Metastasis"},{"key":"2170_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0092-8674(00)81280-5","volume":"84","author":"DA Lauffenburger","year":"1996","unstructured":"Lauffenburger DA, Horwitz AF: Cell migration: a physically integrated molecular process. Cell. 1996, 84: 359-369. 10.1016\/S0092-8674(00)81280-5.","journal-title":"Cell"},{"key":"2170_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10585-007-9065-y","volume":"24","author":"S Hiscox","year":"2007","unstructured":"Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI: Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis. 2007, 24: 157-167. 10.1007\/s10585-007-9065-y.","journal-title":"Clin Exp Metastasis"},{"key":"2170_CR22","doi-asserted-by":"publisher","first-page":"11954","DOI":"10.1158\/0008-5472.CAN-06-1666","volume":"66","author":"M Fan","year":"2006","unstructured":"Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 2006, 66: 11954-11966. 10.1158\/0008-5472.CAN-06-1666.","journal-title":"Cancer Res"},{"key":"2170_CR23","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1210\/en.2002-220620","volume":"144","author":"JM Knowlden","year":"2003","unstructured":"Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003, 144: 1032-1044. 10.1210\/en.2002-220620.","journal-title":"Endocrinology"},{"key":"2170_CR24","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early breast cancer triallists' collaborative group E","year":"2005","unstructured":"Early breast cancer triallists' collaborative group E: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016\/S0140-6736(05)66544-0.","journal-title":"Lancet"},{"key":"2170_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"JF Forbes","year":"2008","unstructured":"Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology. 2008, 9: 45-53. 10.1016\/S1470-2045(07)70385-6.","journal-title":"Lancet Oncology"},{"key":"2170_CR26","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1200\/JCO.2007.12.6334","volume":"26","author":"HB Muss","year":"2008","unstructured":"Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE: Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008, 26: 1956-1964. 10.1200\/JCO.2007.12.6334.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2170_CR27","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0960-9776(08)70003-1","volume":"17","author":"JC Doughty","year":"2008","unstructured":"Doughty JC: A review of the BIG results: the Breast International Group 1\u201398 trial analyses. Breast. 2008, 17 (Suppl 1): S9-S14. 10.1016\/S0960-9776(08)70003-1.","journal-title":"Breast"},{"key":"2170_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-006-9335-4","volume":"102","author":"UW Nilsson","year":"2007","unstructured":"Nilsson UW, Garvin S, Dabrosin C: MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat. 2007, 102: 253-261. 10.1007\/s10549-006-9335-4.","journal-title":"Breast Cancer Res Treat"},{"key":"2170_CR29","first-page":"S81","volume":"14","author":"JM Gee","year":"2004","unstructured":"Gee JM, Shaw V, Burmi R, McClelland R, Morgan H, Harper MHS, Barrow D, Lewis P, Nicholson RI: Array profiling of survival and resistance genes in anti-hormone-treated breast cancer cells. Intl J Mol Med. 2004, 14: S81-","journal-title":"Intl J Mol Med"},{"key":"2170_CR30","first-page":"3706","volume":"46","author":"V Shaw","year":"2005","unstructured":"Shaw V, Gee JMW, McClelland RA, Morgan H, Rushmere N, Nicholson RI: Identification of anti-hormone induced genes as potential therapeutic targets in breast cancer. Proc Amer Assoc Cancer Res. 2005, 46: 3706-","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"2170_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.critrevonc.2004.02.001","volume":"51","author":"N Platet","year":"2004","unstructured":"Platet N, Cathiard AM, Gleizes M, Garcia M: Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol. 2004, 51: 55-67. 10.1016\/j.critrevonc.2004.02.001.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2170_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1023\/A:1018498120910","volume":"15","author":"AC Mathew","year":"1997","unstructured":"Mathew AC, Rajah TT, Hurt GM, Abbas Abidi SM, Dmytryk JJ, Pento JT: Influence of antiestrogens on the migration of breast cancer cells using an in vitro wound model. Clin Exp Metastasis. 1997, 15: 393-399. 10.1023\/A:1018498120910.","journal-title":"Clin Exp Metastasis"},{"key":"2170_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1365-2559.2005.02156.x","volume":"46","author":"EA Rakha","year":"2005","unstructured":"Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO: E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005, 46: 685-693. 10.1111\/j.1365-2559.2005.02156.x.","journal-title":"Histopathology"},{"key":"2170_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10549-006-9248-2","volume":"100","author":"BE Gould Rothberg","year":"2006","unstructured":"Gould Rothberg BE, Bracken MB: E-cadherin Immunohistochemical Expression as a Prognostic Factor in Infiltrating Ductal Carcinoma of the Breast: a Systematic Review and Meta-Analysis. Breast Cancer Res Treat. 2006, 100: 139-148. 10.1007\/s10549-006-9248-2.","journal-title":"Breast Cancer Res Treat"},{"key":"2170_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1600-0463.2007.apm_524.x","volume":"115","author":"D Park","year":"2007","unstructured":"Park D, Karesen R, Axcrona U, Noren T, Sauer T: Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis. APMIS. 2007, 115: 52-65. 10.1111\/j.1600-0463.2007.apm_524.x.","journal-title":"APMIS"},{"key":"2170_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1023\/A:1023772912750","volume":"22","author":"JM Summy","year":"2003","unstructured":"Summy JM, Gallick GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003, 22: 337-358. 10.1023\/A:1023772912750.","journal-title":"Cancer Metastasis Rev"},{"key":"2170_CR37","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1093\/emboj\/16.19.5904","volume":"16","author":"B Boyer","year":"1997","unstructured":"Boyer B, Roche S, Denoyelle M, Thiery JP: Src and Ras are involved in separate pathways in epithelial cell scattering. EMBO journal. 1997, 16: 5904-5913. 10.1093\/emboj\/16.19.5904.","journal-title":"EMBO journal"},{"key":"2170_CR38","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ceb.2005.08.007","volume":"17","author":"E Avizienyte","year":"2005","unstructured":"Avizienyte E, Frame MC: Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol. 2005, 17: 542-547. 10.1016\/j.ceb.2005.08.007.","journal-title":"Curr Opin Cell Biol"},{"key":"2170_CR39","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1210\/en.2006-1269","volume":"148","author":"A Zheng","year":"2007","unstructured":"Zheng A, Kallio A, Harkonen P: Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology. 2007, 148: 2764-2777. 10.1210\/en.2006-1269.","journal-title":"Endocrinology"},{"key":"2170_CR40","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1006\/excr.1996.0221","volume":"226","author":"K Takahashi","year":"1996","unstructured":"Takahashi K, Suzuki K: Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. Exp Cell Res. 1996, 226: 214-222. 10.1006\/excr.1996.0221.","journal-title":"Exp Cell Res"},{"key":"2170_CR41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1242\/jcs.00862","volume":"117","author":"MC Faux","year":"2004","unstructured":"Faux MC, Ross JL, Meeker C, Johns T, Ji H, Simpson RJ, Layton MJ, Burgess AW: Restoration of full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion. J Cell Sci. 2004, 117: 427-439. 10.1242\/jcs.00862.","journal-title":"J Cell Sci"},{"key":"2170_CR42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.yexcr.2005.11.019","volume":"312","author":"AM Carothers","year":"2006","unstructured":"Carothers AM, Javid SH, Moran AE, Hunt DH, Redston M, Bertagnolli MM: Deficient E-cadherin adhesion in C57BL\/6J-Min\/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res. 2006, 312: 387-400. 10.1016\/j.yexcr.2005.11.019.","journal-title":"Exp Cell Res"},{"key":"2170_CR43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ijc.21355","volume":"118","author":"S Hiscox","year":"2006","unstructured":"Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI: Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006, 118: 290-301. 10.1002\/ijc.21355.","journal-title":"Int J Cancer"},{"key":"2170_CR44","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/modpathol.3800362","volume":"18","author":"TL Mastracci","year":"2005","unstructured":"Mastracci TL, Tjan S, Bane AL, O'Malley FP, Andrulis IL: E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol. 2005, 18: 741-751. 10.1038\/modpathol.3800362.","journal-title":"Mod Pathol"},{"key":"2170_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2007.10.009","volume":"44","author":"EA Rakha","year":"2008","unstructured":"Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO: Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008, 44: 73-83. 10.1016\/j.ejca.2007.10.009.","journal-title":"Eur J Cancer"},{"key":"2170_CR46","first-page":"7167","volume":"63","author":"JE Korkola","year":"2003","unstructured":"Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM: Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 2003, 63: 7167-7175.","journal-title":"Cancer Res"},{"key":"2170_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/bcr416","volume":"4","author":"AM Cleton-Jansen","year":"2002","unstructured":"Cleton-Jansen AM: E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?. Breast Cancer Res. 2002, 4: 5-8. 10.1186\/bcr416.","journal-title":"Breast Cancer Res"},{"key":"2170_CR48","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2007.14.9336","volume":"26","author":"BC Pestalozzi","year":"2008","unstructured":"Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A: Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008, 26: 3006-3014. 10.1200\/JCO.2007.14.9336.","journal-title":"J Clin Oncol"},{"key":"2170_CR49","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djk109","volume":"99","author":"Adjuvant Breast Cancer Trials Collaborative Group","year":"2007","unstructured":"Adjuvant Breast Cancer Trials Collaborative Group: Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst. 2007, 99: 516-525. 10.1093\/jnci\/djk109.","journal-title":"J Natl Cancer Inst"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr2206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/bcr2206\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr2206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:49:27Z","timestamp":1728384567000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr2206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,4]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,12]]}},"alternative-id":["2170"],"URL":"https:\/\/doi.org\/10.1186\/bcr2206","relation":{},"ISSN":["1465-542X"],"issn-type":[{"type":"electronic","value":"1465-542X"}],"subject":[],"published":{"date-parts":[[2008,12,4]]},"assertion":[{"value":"6 June 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R103"}}